Kornimate/medical-research-clean huggingface dataset:
vitamin d supplementation and wbv in inflammatory markers, strength and body composition in old patients with copd

Conditions: COPD; Aging

Summary: verify the influence off vitamin d supplementation and a whole body vibration (wbv) protocol during 03 months in older patients chronic obstructive pulmonary disease


Eligibility criteria:
inclusion criteria: * older patients with copd * both genders * sedentary according to international physical activity questionnaire (ipaq) short form * bmi in between 22.9 and 28 kg/m2. * older patients with copd should have a clinical-functional diagnosis of the disease according to gold (gold, 2018), have been ex-smokers and have not used corticosteroids or have used this drug in a stable way for at least one year (without dosage or medication modifications). * older volunteers should be self-referenced healthy or, if they had systemic arterial hypertension or diabetes mellitus, these comorbidities should be controlled by diet or regular medication use. exclusion criteria: * older patients with copd who had episodes of exacerbation in the last three months, those with pulmonary rehabilitation programs in the last year, those who used home oxygen therapy, and patients with copd associated comorbidities were excluded. * volunteers of both groups who were taking vitamin d were excluded, as well as the current smokers, although occasional, volunteers with a history of labyrinthitis or thromboembolism, who had undergone surgical procedures of any size in the last year, such as plaques, pins or cardiac pacemakers, those with unconsolidated fractures that used medications that affected bone metabolism or lean mass, or those who had difficulties adapting to the assessment or the training protocol.
effect of vitamin d supplementation in live birth rate of in vitro fertilization outcome

Conditions: Infertility

Summary: this is a randomized-controlled trial evaluating the effect of the use of vitamin d supplementation on the live birth rate in women undergoing in vitro fertilization (ivf). the hypothesis is that administration of vitamin d can increase the live birth rate for women undergoing ivf.

patients undergoing ivf treatment cycle at queen mary hospital and kwong wah hospital will be invited to participate in this study. participating subjects will be randomized into either (i) vitamin d or (ii) placebo group in a 1:1 allocation ratio by computer-generated random numbers one month before ivf. subjects allocated to the vitamin d group will take vitamin d 50,000iu per week from recruitment for 4 weeks, followed by 50,000iu once every 2 weeks throughout the ivf cycle until fetal viability is confirmed at 6 weeks (if pregnant), after which they will be switched to materna. if not pregnant, they will continue vitamin d 50,000iu once every 2 weeks until 6 months from randomization, during which they can undergo frozen-thawed embryo transfer. subjects allocated to the placebo group will take placebo tablets which will be identical to the active drug. if pregnant and fetal viability is confirmed at 6 weeks, they will be switched to materna. if not pregnant, they will continue the placebo tablets until 6 months from randomization, during which they can undergo frozen-thawed embryo transfer. the clinician and patients will both be blinded to the randomization throughout the course of treatment. the live birth rate of the two groups will be compared.

Eligibility criteria:
inclusion criteria: * infertile women undergoing ivf * aged between 18 and 43 years old, inclusive, at the time of signing informed consent * having given voluntary written informed consent exclusion criteria: * already taking vitamin d * undergoing preimplantation genetic testing * use of donor oocytes or donor embryos * presence of hydrosalpinx not corrected surgically * active tuberculosis/ receiving therapy for tuberculosis * history of any medical condition or medications that may predispose to vitamin d sensitivity, altered vitamin d metabolism and/or hypercalcemia, including history of renal/ureteral stones, parathyroid disease, renal or liver failure, current use of anticonvulsants, current use of steroid * allergy to vitamin d * abnormal serum calcium values
a phase 2, randomized, open-label study of single agent ci-1033 in patients with advanced non-small cell lung cancer

Conditions: Lung Neoplasms

Summary: the purpose of study to determine the activity of ci 1033 against tumors in patients with advanced or metastatic nsclc who have failed prior platinum-based combination chemotherapy. another objective is to determine the safety of ci 1033.


Eligibility criteria:
inclusion criteria: * histologically or cytologically documented diagnosis of progressive or recurrent, locally advanced or metastatic nsclc; a tumor that expresses at least one member of the erbb family of receptors; failed or relapsed after receiving a platinum-containing regimen as therapy; at least one measurable target lesion as defined by recist that has not been irradiated. exclusion criteria: * prior exposure to agents that target the erbb receptor family; unknown response to prior platinum-containing chemotherapy regimen; cytotoxic chemotherapy within 3 weeks prior to baseline disease assessments (6 weeks for nitrosoureas or mitomycin); more than 2 prior chemotherapy regimens: immunotherapy or other biologic therapy within 2 weeks prior to baseline disease assessment; prior irradiation to areas encompassing greater than 30% of marrow-bearing bone; brain metastases.
evaluation of the efficacy of internal family systems (ifs) therapy

Conditions: PTSD; Depression

Summary: study examining the effectiveness of 16 weeks of internal family systems (ifs) therapy for adults with posttraumatic stress disorder (ptsd).

evaluation study of ifs therapy among trauma-impacted adults in order to explore the applicability of ifs with this population, ensure fidelity of treatment administration, and examine initial efficacy. evaluate the utility of ifs in reducing symptoms of ptsd, dissociation and depression and increasing self-regulatory capacity, self-awareness and self-compassion. 15 subjects between the ages of 18 and 56 who are receiving 16, 90-minute sessions of ifs therapy by certified ifs practitioners in the community will be recruited for this evaluation study. blind evaluators will assess treatment effects at pre-treatment, mid-treatment, post-treatment and at one-month follow-up, measuring change in symptoms of ptsd, dissociation and depression, as well as self-regulation, self-compassion, and interoceptive awareness.

Eligibility criteria:
inclusion criteria: * individuals between 18 and 58 years old, any race. * a minimum two traumatic events prior to the age of 18 years. * current ptsd diagnosis per caps assessment with total symptom scores indicative of a moderate degree of severity (i.e. caps total score between 55 and 80). * clinically significant depressive symptoms as indicated by a total score of 14 or above on the bdi. exclusion criteria: * gaf \< 40. * diagnosis of schizophrenia, did, bipolar disorder or other psychotic disorder not stated above. * substance dependence or abuse in the past 6 months, as defined by dsm iv criteria and judged by the pi. * current legal proceedings resulting from the traumatic events. * previous treatment in ifs.
nerve growth factor for the treatment of cornea disease

Conditions: Neurotrophic Keratitis

Summary: to determine the efficacy and safety of nerve growth factor in the treatment of limbal stem cell deficiency (lscd) associated with neurotrophic cornea.

this is a prospective open-label pilot study evaluating the role of cenegermin-bkbj for the treatment of lscd with associated neurotrophic keratopathy. patient diagnosed with lscd with neurotrophic cornea who have failed conventional treatment such as artificial tears are enrolled in the study after a 2 week washout period. patient are then treated with cenegermin-bkbj over an 8 week period.

Eligibility criteria:
inclusion criteria: patients diagnosed with lscd and neurotrophic cornea confirmed by testing with cochet-bonnet aesthesiometer exclusion criteria: 1. active ocular infection 2. anticipated need for bandage contact lens, amniotic membrane graft, or tarsorrhaphy during the study period 3. unable to discontinue the use of contact lens 4. visual acuity worse than 20/200 in the better eye
impact of subcutaneous electric lumbar stimulation on treatment of refractory chronic and disabling lumbago

Conditions: Pain

Summary: the aim of the study is to show that subcutaneous electric lumbar stimulation reduces pain in chronic lumbago after 12 months of treatment.


Eligibility criteria:
inclusion criteria: * patients over 18 years old * having given their non-opposition * affiliated to a national insurance scheme or beneficiary * suffering for more than a year from a chronic, invalidating lumbago that is refractory in several lines of treatments exclusion criteria: * patients with lumbago that can be surgically handled or which justified a medullary stimulation * having been operated for the rachis for less than 6 months; * which cannot for cognitive or cultural reasons contribute to the planned evaluations and to the management of the material (remote control); * for who the investigator can plan that they cannot be followed during one year from the date of the setting-up (non-observance, planned moving, etc.); * which present psychological, local or general contraindications to the setting-up of a neurostimulation device (impossibility to stop anticoagulants or aggregation inhibitors, disturb of the hemostasis, cutaneous infection change on the site of setting-up) * mri planned within the next year * pregnant or breast-feeding women.

Keywords: subcutaneous stimulation
atralin gel for the treatment of rosacea

Conditions: Rosacea

Summary: erythematotelangiectatic rosacea is a type of rosacea that causes a red face often with frequent flushing, topical sensitivity and prominent blood vessels. we think that long term damage to skin from the sun (photodamage) may play a role in causing this type of rosacea. tretinoin is a topical medication that is known to improve photodamage. we want to find out if atralin (tretinoin 0.05%) gel used for up to 46 weeks will improve erythematotelangiectatic rosacea (etr).


Eligibility criteria:
inclusion criteria: 1. subjects 18 years of age and older of any race. 2. clinical diagnosis of mild to moderate erythematotelangiectatic facial rosacea based on physician evaluation. 3. willing and able to understand and sign informed consent. 4. able to complete study and comply with study procedures. exclusion criteria: 1. severe self reported facial sensitivity 2. history of allergy to fish 3. severe sun sensitivity 4. severe erythematotelangiectatic rosacea requiring systemic treatment 5. papulopustular, ocular-only, phymatous rosacea, steroid rosacea, pyoderma faciale 6. unwilling to undergo facial biopsies 7. concomitant use of medications that are reported to exacerbate rosacea, such as topical and systemic steroids 8. use of topical rosacea treatments in the past 2 weeks. 9. use of systemic antibiotics in the past 4 weeks. 10. use of systemic retinoids within the past 6 months. 11. use of topical retinoids within the past 3 months 12. use of laser or light based rosacea treatments within the past 2 months. 13. cosmetic procedures (e.g., superficial chemical peels, exfoliation or microdermabrasion of the face) within the past two months 14. use of topical anti-aging medications including alpha hydroxy acids, salicylic acid, beta-hydroxy acid, vitamin a, vitamin e, ascorbic acid 15. other dermatologic conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments. 16. clinically significant abnormal findings or conditions (other than rosacea), which might, in the opinion of the investigator, interfere with study evaluations or pose a risk to subject safety during the study. 17. if female, subjects who are either of non-child bearing potential (defined as postmenopausal -absence of menstrual bleeding for 1 year - or as having undergone bilateral tubal ligation, hysterectomy or bilateral ovariectomy) or, if of childbearing potential, subjects who have had a negative urine pregnancy test at the beginning of the study, and have agreed to practice appropriate birth-control to prevent pregnancy during the study.(the type and dose of birth control must have been stable for at least 2 months prior to study entry and not be expected to change during the study). 18. subjects who are lactating. 19. use of any investigational therapy within the past 4 weeks. 20. known hypersensitivity or previous allergic reaction to retinoids 21. carcinoid, pheochromocytoma or other systemic flushing causes

Keywords: rosacea tretinoin atralin
almonds and diabetes management

Conditions: Type 2 Diabetes

Summary: this trial examined the impact of acute and chronic almond ingestion on indicators of glucose control (postprandial glycemia and hemoglobin a1c). hypotheses: 1. almonds will stimulate the secretion of glp-1 in healthy adults and in adults with t2d the investigators were not able to demonstrate a relationship between glp-1 secretion and almond consumption. individuals with t2d were characterized with significantly greater glp-1 secretion than the non-diabetic control subjects. 2. acute ingestion of almonds will decrease the postprandial glycemia and insulinemic responses in healthy controls and in individuals with t2d the investigators data support the hypothesis: almond consumption by individuals with t2d did attenuate postprandial glycemia; however, almond consumption did not alter glycemia in non-diabetic control subjects 3. chronic almond ingestion for 12 weeks will reduce fasting glucose (fg) and a1c concentrations in individuals with t2d the investigators data demonstrated modest beneficial effect of almond consumption on a1c in individuals with t2d. almond consumption was also associated with modest weight loss as compared to the control treatment (low fat cheese sticks).


Eligibility criteria:
inclusion criteria: * 12 subjects with diagnosed t2d for at least 1 year and 12 healthy individuals without t2d will be recruited for the acute almond trial. * 24 subjects with diagnosed t2d for at least 1 year will be recruited for the chronic almond trial. * subjects from the campus population and nearby communities will be recruited to participate in these trials. * men and women must be willing to comply with the experimental protocol including the restriction of nut consumption: * subjects recruited for the acute almond study must agree not to consume any nuts or nut butters for 1-week prior to and during the 2-week trial * participants in the chronic almond study must agree not to consume nuts or nut butters more than 2 times per week during the 12 week trial. * participants must have a body mass index (bmi) from 20 to 35 kg/m2 and are aged 30 to 70 years. * subjects with t2d may take oral hyperglycemic agents. exclusion criteria: * insulin use * history of a peanut allergy * chronic or unresolved disease * current smoking habit * pregnant or lactating * medication use that may impact incretin secretion. \[incretins are gastrointestinal hormones secreted at meal-time.\]
efficacy and safety of olanzapine in the extended treatment for manic or mixed episode of bipolar i disorder

Conditions: Manic or Mixed Episode Associated With Bipolar I Disorder

Summary: the efficacy and safety of the extended treatment to patients with most recent episode manic or mixed who completed previous double blind study (f1d-je-bmac \[study bmac\]) will be examined.


Eligibility criteria:
inclusion criteria: * enrolled in and completed study bmac (nct00129220), or those who discontinued study bmac at visit 4 or visit 5 due to lack of efficacy and for whom the young mania rating scale (ymrs) total score at the time of discontinuation was not lower than that at baseline of study bmac * are diagnosed as "294.4x bipolar i disorder, most recent episode manic" or "296.6x bipolar i disorder, most recent episode mixed," as determined by the mini-international neuropsychiatric interview (mini) exclusion criteria: * have a diagnosis of diabetes mellitus * significant protocol deviation in study bmac * the actual date of the final visit of study bmac is 4 days or more later than the scheduled date of first visit in study bmex
corneal protect used during cataract surgery

Conditions: Cataract

Summary: this randomized controlled subject- and examiner-masked study comprised patients scheduled for cataract surgery.the patients will be randomly assigned to receive either balanced salt solution（bss）or hydroxypropyl methylcellulose（hpmc）2% gel （cornea protect）.each subject should undertake examination including - rupture time (tbut), height of the river of tears, fluorescence staining, schirmer ⅰ test, ocular surface disease index (osdi) and self-conscious symptom assessment questionnaire for assessment.

this randomized controlled subject- and examiner-masked study comprised patients scheduled for cataract surgery.over 100 patients will be randomly assigned to receive either balanced salt solution（bss）or hydroxypropyl methylcellulose（hpmc）2% gel （cornea protect）.each subject will accept 5 times assessments:the day before surgery, surgery day , the day after surgery,a week after surgery and a month after surgery.each time a subject should undertake examination including - rupture time (tbut), height of the river of tears, fluorescence staining, schirmer ⅰ test, ocular surface disease index (osdi) and self-conscious symptom assessment questionnaire et.al.the purpose is to evaluate the effect of cornea protect to maintain intraoperative clarity and to prevent the postoperative xerophthalmia.

Eligibility criteria:
inclusion criteria: * with cataracts; * aged 40 to 85 years old, gender not limited; * plans to accept phaco and intraocular lens(iol)implantation surgery * the lens nucleus hardness level is less than 3 ; * signed informed consent. exclusion criteria: * allergic to any of the drugs or device in this study ； * existence of other infectious diseases or allergic conjunctivitis. * the eye had been chemical burned or thermal burned * diagnosed as stevens johnson syndrome or eye-pemphigoid. * diagnosed with glaucoma or high intraocular pressure; * existence of eyelid and lacrimal duct disease; * received any eye surgery in 3 months; * wearing corneal contact lens; * history suggests there are serious heart, lung, liver or renal function disorder; * pregnancy or lactation women; * other conditions considered not appropriate by the investigators.

Keywords: cataract surgery cornea protect xerophthalmia corneal clarity
ucp glaucoma treatment for primary glaucoma in china

Conditions: Glaucoma Treatment Using Focused Ultrasound

Summary: to collect safety and efficacy data on ultrasound cycle plasty treatment (ucp) in primary glaucoma asian patients.


Eligibility criteria:
inclusion criteria: * primary open angle and primary angle closure glaucoma * subject where the iop is not adequately controlled with glaucoma medication, and can not or not agree for incisional glaucoma surgery * iop ≥ 21 mmhg and ≤ 40 mmhg * best corrected visual acuity \> hand motion * patient able and willing to sign the informed consent and complete postoperative followup requirements exclusion criteria: * history of ocular or retrobulbar tumor * ocular infection within 14 days prior to the procedure of ultrasound cyclo plasty (ucp) * history of cyclo-destructive procedures (cryotherapy, laser transscleral cyclophotocoagulation; laser endophotocoagulation) * congenital glaucoma * history of ciliary body surgery or vitrectomy in the study eye * ocular disease other than glaucoma that may affect assessment of visual acuity and/or iop (choroidal hemorrhage or detachment, lens subluxation, thyroid ophthalmopathy, proliferative diabetic retinopathy, clinical significant macular edema, retinal detachment)

Keywords: glaucoma, ciliary body, ultrasound
clinical phenotyping and genotyping of hiv-associated sensory neuropathy: the hiv-pogo study

Conditions: HIV; Sensory Neuropathy; Neuropathic Pain

Summary: this study aims to recruit a cohort of hiv patients with and without hiv-sn and to identify genetic risk factors for the development of hiv-sn and neuropathic pain. it also aims to more deeply phenotype the condition, using well validated questionnaires, and to identify any influence that early neurocognitive dysfunction may have on the reporting, diagnosis and treatment of neuropathic pain in the hiv population.

hiv associated sensory neuropathy (hiv-sn) is a frequent complication of hiv infection, affecting between 20 and 57% of infected individuals. the advent of better antiretroviral treatment for hiv has meant that mortality from hiv has decreased dramatically in the uk. this means however, that chronic, age-related conditions associated with hiv, such as hiv-sn and cognitive impairment, are increasing in prevalence and becoming a significant disease burden. the classification, diagnosis and treatment of hiv-sn remains poor. currently, little is known about the genetic basis of the disorder and what risk factors mean that some patients with hiv develop neuropathy and pain, whilst others do not. it is hoped that by further characterising or 'phenotyping' the disorder, it will be easier to identify which patients are at risk of developing neuropathy and chronic pain. it may also mean that treatment can be more individualised as currently patients often undergo a frustrating 'trial and error' protocol of treatment, as clinicians can not yet predict who will respond to which treatment. it has also been suggested that there is a link between hiv-sn and hiv associated neurocognitive disorder (hand), which is another common, age-related complication of hiv infection. it may be that the existence of one pathology could predict the development of the other, or that the presence of hand may impair the diagnosis or treatment of chronic pain associated with hiv-sn.

Eligibility criteria:
inclusion criteria: * aged 18 years or over * hiv infection exclusion criteria: * co-incident severe neurological disease * co-incident severe psychiatric illness * limited english language skills so as not able to conduct quantitative sensory testing * pregnancy * pain of greater than 3/10 on an nrs due to pathology other than hiv-sn

Keywords: hiv sensory neuropathy
study of alpha-blockers alone during preoperative preparation in patients with pheochromocytoma

Conditions: Adrenal Pheochromocytoma; Hemodynamic

Summary: study of the relationship between hemodynamic stability and preoperative intravenous rehydration in patients with pheochromocytoma

all patients were subclassified into either the hemodynamic stability group (hs group) or the hemodynamic instability group (hu group) according to whether intraoperative hemodynamic instability occurred. differences in data between the two groups were examined, and the risk factors for intraoperative hemodynamic instability were analyzed using logistic regression.

Eligibility criteria:
inclusion criteria: clinical diagnosis of adrenal pheochromocytoma must be able to swallow tablets exclusion criteria: bilateral or multiple pheochromocytomas. ectopic pheochromocytoma
non-surgical treatment of knee osteoarthritis - a comparison of effects in 2200 patients

Conditions: Knee Osteoarthritis

Summary: the purpose of this study is to assess whether radiographic osteoarthritis severity (oa; kellgren-lawrence scale) is associated with self-reported improvement in pain after non-surgical treatments (physiotherapy, pain killers, injection, other treatments). the hypothesis is that radiographic oa severity is inversely associated with self-reported improvement.


Eligibility criteria:
inclusion criteria: * not eligible for at total knee arthroplasty exclusion criteria: * ipsilateral knee arthroplasty